Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

[1]  L. Sehn,et al.  Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study , 2018, Blood.

[2]  Ramsis Benjamin,et al.  Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors , 2018, Annals of Hematology.

[3]  Weirong Wang,et al.  Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents , 2018, mAbs.

[4]  Hans Anton Schlößer,et al.  Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.

[5]  D. Mager,et al.  Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity , 2018, Clinical Cancer Research.

[6]  P. Kufer,et al.  Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma , 2018, Current clinical pharmacology.

[7]  S. Ramanujan,et al.  A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies , 2018, Clinical and translational science.

[8]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[9]  Stephen J. Schuster,et al.  Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.

[10]  Saroja Ramanujan,et al.  Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model , 2017, npj Systems Biology and Applications.

[11]  J. Friedberg,et al.  Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1 , 2016 .

[12]  H. Einsele,et al.  Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Xuan,et al.  Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach , 2016, Clinical pharmacology and therapeutics.

[14]  C. Klein,et al.  CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors , 2016, Oncoimmunology.

[15]  A. Wolf,et al.  Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications , 2016, Clinical Pharmacokinetics.

[16]  M. Pfreundschuh,et al.  Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. , 2016, Blood.

[17]  R J Allen,et al.  Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models , 2015, bioRxiv.

[18]  Diego Ellerman,et al.  Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies , 2015, Science Translational Medicine.

[19]  J. Mauer,et al.  Versatile functions for IL-6 in metabolism and cancer. , 2015, Trends in immunology.

[20]  T. Waldmann,et al.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  John D. Davis,et al.  A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations , 2014, CPT: pharmacometrics & systems pharmacology.

[22]  Marcela V Maus,et al.  Antibody-modified T cells: CARs take the front seat for hematologic malignancies. , 2014, Blood.

[23]  D. Teachey,et al.  Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.

[24]  Diego Ellerman,et al.  Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies , 2013, Nature Biotechnology.

[25]  D. Teachey,et al.  Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017-4023. , 2016, Blood.

[26]  Sharmila Binte Shamshad Ali Rn Dip.  Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia , 2013 .

[27]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[28]  P. Kufer,et al.  Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.

[29]  Delong Liu,et al.  CD19: a biomarker for B cell development, lymphoma diagnosis and therapy , 2012, Experimental Hematology & Oncology.

[30]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[31]  H. Einsele,et al.  Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma , 2011 .

[32]  H. Einsele,et al.  Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m2/d Is Tolerable and Highly Effective , 2010 .

[33]  T. Tedder.  CD19: a promising B cell target for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[34]  H. Langer,et al.  Leukocyte – endothelial interactions in inflammation , 2009, Journal of cellular and molecular medicine.

[35]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[36]  P. Kufer,et al.  T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct , 2006, Cancer Immunology, Immunotherapy.

[37]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[38]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Mark M Davis,et al.  A New Trigger for T Cells , 2002, Cell.

[40]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[41]  R. Jain,et al.  Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model. , 2002, Neoplasia.

[42]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[43]  J. Wells,et al.  Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. , 1997, Journal of molecular biology.

[44]  M. Atkins,et al.  Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.